





Clinical Tuberculosis

Second Edition

JOHN CROFTON • NORMAN HORNE
FRED MILLER



Clinical Tuberculosis

Second Edition

Sir John Crofton KB MD(Camb) FRCPEd and Lond
Professor Emeritus of Respiratory Diseases and Tuberculosis,
University of Edinburgh

Norman Horne MB ChB FRCPEd
Formerly Consultant Physician, Chest Unit, City Hospital,
Edinburgh

The late
Fred Miller MD FRCP DCH
Formerly Honorary Physician, The Children's Department,
Royal Victoria Infirmary, Newcastle upon Tyne

Sponsored by the International Union Against Tuberculosis and
Lung Disease and by TALC (Teaching Aids at Low Cost)



IUATLD



© Copyright text J. Crofton, N. Horne, F. Miller, 1992, 1999

© Copyright illustrations J. Crofton, N. Horne, F. Miller, 1992, 1999

Any parts of this book, including the illustrations, may be copied, reproduced, or adapted to meet local needs, without permission from the authors or publisher, provided the parts reproduced are distributed free or at cost – not for profit. For any reproduction with commercial ends, permission must first be obtained from the publisher or authors. The publisher and authors would appreciate being sent a copy of any materials in which text or illustrations have been used.

First edition 1992

Reprinted twice

ELBS edition 1994

Second edition 1999

Published by

MACMILLAN EDUCATION LTD

London and Basingstoke

Companies and representatives throughout the world

ISBN 0-333-72430-5

10	9	8	7	6	5	4	3	2	1
08	07	06	05	04	03	02	01	00	99

This book is printed on paper suitable for recycling and made from fully managed and sustained forest sources.

Printed in Malaysia

A catalogue record for this book is available from the British Library.

Acknowledgements

The authors and publishers wish to thank the following for permission to use copyright material:

Aids International for Table 17 from D J Girling, 'Adverse effects of anti-tuberculosis drugs', *Drugs*, 23 (1982) 56-74;

Churchill Livingstone for Figure 17 from F J W Miller, *Tuberculosis in Children*, New Delhi, Churchill Livingstone (1986);

World Health Organization for Table 13, Table 16 from WHO data and information; and for adapted material in Chapter 5 from 'TB/HIV: A Clinical Manual', Geneva, WHO (1996);

Every effort has been made to trace the copyright holders but if any have been inadvertently overlooked the publishers will be pleased to make the necessary arrangement at the first opportunity.

The Authors

Sir John Crofton became Professor of Respiratory Diseases and Tuberculosis at Edinburgh University in 1952. He has been Chairman of the International Union Against Tuberculosis and Lung Disease's tuberculosis treatment and tuberculosis diagnostic scientific committees, and a member of WHO's Consultative Panel on TB. He has lectured and advised in over 50 countries.

Norman Horne was President, Europe Region, of the International Union Against Tuberculosis and Lung Disease from 1982 to 1988, and has been Chairman of the Chest Heart and Stroke Association of Scotland since 1982. Formerly he was President of the British Thoracic Association, and WHO Visiting Professor in Medicine, Baroda, India.

Fred Miller was a consultant paediatrician and undertook many assignments for WHO, chiefly in India. He also wrote the book *Tuberculosis in Children* (Churchill Livingstone, 1982).

Foreword to First Edition

The International Union Against Tuberculosis and Lung Disease welcomes *Clinical Tuberculosis* with interest, gratitude and pride.

Interest, because clinical aspects are part and parcel of the essential knowledge necessary both to those dealing with the individual and those dealing with the community.

Gratitude, because precisely this type of manual for non-specialised practitioners and public health field workers was long and badly needed.

Pride, because the book is the result of the collaborative effort of two long-standing highly respected members of the Union, and a paediatrician, all of them with an immense experience with tuberculosis patients as well as with the problems and needs at national and international levels. The book bears witness to their indefatigable drive in trying to impart useful know-how to their colleagues and fellow workers striving under difficult conditions.

We now possess well established methods for prevention, diagnosis and treatment of tuberculosis as well as the concept of National Tuberculosis Programmes; the latter provide the system through which the effective means can be delivered.

Recent studies have re-awakened our awareness as to the magnitude of the problem: tuberculosis remains the biggest killer in the world as a single pathogen; while it hits children as well as elderly, the worst affected are adults between 15 and 59 years of age i.e. the parents, workers and leaders in society. Tuberculosis accounts for 26 per cent of all avoidable deaths in Third World countries.

The tremendous toll of tuberculosis is increasing in many countries due to the interaction of HIV and tuberculosis infections. However tuberculosis remains curable even in the HIV infected. The present remobilisation against the ancient scourge tuberculosis will, hopefully, be able to curb the present flaring up of incidence.

Moreover cost-benefit analyses have shown that short-course chemotherapy of tuberculosis, within the framework of national programmes, is one of the cheapest of all health interventions, comparable in cost to immunization for measles or to oral rehydration therapy for diarrhoea.

Those who fight tuberculosis, this inseparable but terrible companion of man, will find this comprehensive and clear book a mighty ally to assist them accomplish their mission with more competence, more understanding and more humanity, and will bring closer the time when proper diagnosis and adequate management of cases will stop the perpetuation of the disease, thus paving the way to its elimination.

Annik Rouillon, MD, MPH
Executive Director,
International Union Against Tuberculosis
and Lung Disease

Preface to the Second Edition

Professor David Morley, the Honorary Director of Teaching Aids at Low Cost (TALC), originally asked the authors to write this book for non-specialist doctors and health professionals in countries with a high prevalence of tuberculosis. We found it a fascinating challenge to try to produce a book in simple language which could be useful to workers who might have very few resources. The book was to be primarily about clinical tuberculosis. But we felt that clinical tuberculosis should be put in a framework of a National Tuberculosis Control Programme. Only in that framework could the mass of patients be effectively diagnosed and cured. Only in that framework could mass cure lead to mass prevention.

We had hoped that at least some doctors and health professionals in some countries would find the book useful. In the event it does seem to have met a real need. The demand has exceeded our wildest expectations. We initially arranged for French, Spanish and Portuguese translations, so as to make it available to the appropriate countries in Africa and America. But we have been delighted to find that many countries have wished to produce editions in their own languages. As we write (1997) it has appeared in fourteen languages, with editions in four others in various stages of preparation. Besides the languages already mentioned there are editions in Russian, Italian, Croatian, Chinese, Mongolian, Thai, Vietnamese, Arabic, Farsi (Iran) and Turkish. We are expecting future editions in Romanian, Indonesian, Urdu and Bengali. We are most grateful to the translators, publishers and distributors of all these editions. A preliminary estimate is that more than 70,000 copies in the various languages have been distributed in 125 countries. The book has been used by the World Health Organization and the International Union Against Tuberculosis and Lung Disease, and we hope by others, for their training courses.

In producing our first edition we had much help from a series of international experts. These included Professors John Biddulph (Papua New Guinea) and David Morley (TALC and UK); Drs Andrew Cassels (UK), Keith Edwards (Papua New Guinea), A.D. Harries (UK and Malawi), Wendy Holmes (Zimbabwe and Australia), Kanwar K. Kaul (India), A. Kochi (WHO), Colin McDougall (UK), S.J. Nkinda (Ethiopia),

Knut Ovreberg (Norway and IUATLD), S.P. Pamra (India), C.A. Pearson (UK and Nigeria), Annik Rouillon (France and IUATLD), Sergio Spinaci (WHO), Karel Styblo (Netherlands and IUATLD), H.G. ten Dam (WHO), Yan Bi-Ya (China). Once more we record our gratitude to them.

In preparing this second edition we have benefited from much discussion with international experts, notably those from WHO and IUATLD. In particular we thank Dr Hans Rieder of IUATLD who re-read our first edition in detail and made many helpful suggestions which we have incorporated.

The major changes in the present edition are in the chapters on HIV and tuberculosis and in the sections on chemotherapy. Since the first edition there is now much more experience of HIV. We have greatly expanded that chapter. In doing so we have utilised extensively the WHO publication *TB/HIV. A Clinical Manual* by Drs A.D. Harries and D. Maher (1996). We are most grateful to Dr Harries for constructive criticism of a draft of our chapter.

We have revised the sections on chemotherapy to make sure that they are consistent with the second (1997) edition of WHO's *Treatment of Tuberculosis. Guidelines for National Programmes*. We have also revised the Appendix on tuberculin testing in the light of recent recommendations by the International Union Against Tuberculosis and Lung Disease and informal discussions with WHO staff.

Much work has been done in recent years on 'molecular' aspects of tuberculosis. The detection of specific components of tubercle bacilli may ultimately lead to rapid diagnosis of disease and to rapid detection of drug resistance. Genetic classification of sub-strains of bacilli can already identify sources of local outbreaks. But none of the new methods is so far sufficiently simple, reliable and cheap for general use in poorer countries. So we have not included any details. The search continues for new drugs but none has yet proved sufficiently effective, non-toxic and cheap to find a place in routine treatment. In all these fields look out for new developments.

Sadly, we have to record the death in 1996 of our co-author Fred Miller. He made an outstanding contribution to the book. We hope the book will stand as a memorial to his remarkable work for paediatrics, and in particular for paediatric tuberculosis, in many countries. We miss him sorely.

ACKNOWLEDGEMENT OF FINANCIAL SUPPORT

Britain Nepal Medical Trust
Catholic Association for Overseas Development (CAFOD)
Chest, Heart and Stroke, Scotland
Christian Aid, United Kingdom
Community Health and Anti-tuberculosis Association of New South
Wales, Australia
Damien Foundation, Belgium
Department of Child Health, University of Newcastle, UK
Global Tuberculosis Programme, World Health Organization
Professor Dafyd Jenkins, Wales
Landsforeningen for Hjerte-og Lungesyke, Norway
MISEREOR, Germany
NORAD, The Norwegian Agency for Development Cooperation
The Norwegian National Health Association
OXFAM, United Kingdom
Thoracic Society of Australia and New Zealand
Victoria Tuberculosis and Lung Association, Australia

In addition some translations have received support for publication from their own national donors.

Contents

Foreword to First Edition	xi
Préface to Second Edition	xiii
Acknowledgements of Financial Support	xv
Chapter 1 General Background to Clinical Tuberculosis	1
1: Introduction	1
1.1 About this book	1
1.2 Some of the things you should know	1
1.3 The world problem of tuberculosis	2
1.4 The outlook	2
1.5 Tuberculin surveys and annual numbers of new cases	2
1.6 Treatment	3
2: General Guidelines on the Treatment of Tuberculosis	3
2.1 DOs and DON'Ts for doctors	3
2.2 Guidelines on tuberculosis for non-medical health staff	5
3: The Battle Between the Tubercle Bacilli and the Patient	7
3.1 Causes of tuberculosis: the bacillus	7
3.2 Infection and disease	8
3.3 Where infection comes from (sources of infection)	9
3.4 Lessons for prevention	10
3.5 How a person resists infection (host defences)	11
3.6 Lessons for prevention	13
3.7 BCG	14
4: Tuberculosis Control Programmes	15
4.1 Introduction	15
4.2 Components of a National Tuberculosis Control Programme	17
<i>How to manage family contacts</i>	23
4.3 Conclusions	24
4.4 Integration of control programme into primary health care	24
Chapter 2 Tuberculosis in Children	29
1: Infection with Tuberculosis	29
1.1 How children are infected	29
1.2 The changes after infection	30
<i>Some stories about primary tuberculosis and its complications</i>	37
1.3 The timetable and risks of primary infection	41
1.4 The effect of age at infection, nutrition and other infections and infestations	43
2: Meeting the Child who might have Tuberculosis	44
2.1 When to think of tuberculosis	44
2.2 Important points to remember	45
2.3 How to plan action – recording of a child suspected to be tuberculous	45
2.4 Plan of action	47
3: How Tuberculosis shows in Children	50
3.1 In the lungs	50
<i>Three stories about milinary tuberculosis</i>	52
3.2 Infection in the mouth or ear	55

3.3	Abdominal tuberculosis	55
	<i>A patient with abdominal tuberculosis</i>	56
3.4	Tuberculosis of the lymph nodes	56
3.5	Tuberculosis of brain and spinal cord	58
	<i>Three patients with tuberculous meningitis</i>	59
3.6	Tuberculosis of bones and joints	62
	<i>An adult patient with spinal tuberculosis complicated by paraplegia</i>	65
	<i>A patient with tuberculosis of the hip following a fall</i>	67
	<i>A patient with tuberculosis of the elbow joint</i>	68
3.7	Tuberculosis of the eye	69
3.8	Tuberculosis of the skin	72
3.9	Unusual places for children's tuberculosis	73
3.10	Infection before or during birth or in the newborn period	75
4:	How You can Help and Treat Tuberculous Children	76
4.1	Anti-tuberculosis medicines	76
4.2	Other medicines	79
4.3	Food and nutrition	79
4.4	Immunisation and protection	80
4.5	Always remember	82
5:	HIV Infection, AIDS (Acquired ImmunoDeficiency Syndrome) and Tuberculosis in Children	82
5.1	Where infection comes from	82
5.2	Diagnosis	83
5.3	Age when children become ill	83
5.4	Ways in which HIV infection shows in children	83
5.5	Diagnosing it from other diseases	84
5.6	Prognosis	85
5.7	Tuberculosis in HIV infected children	85
5.8	Counselling	85
5.9	HIV infection and BCG	86
	References	86
	 Chapter 3 Pulmonary Tuberculosis in Adults	 87
1:	Lung Tuberculosis in Adults	87
1.1	How pulmonary tuberculosis develops in adults	87
1.2	Meeting the adult who might have pulmonary tuberculosis (symptoms and physical signs)	90
1.3	Investigations	92
1.4	X-ray (radiological) examination	95
1.5	Tuberculin test	96
1.6	Blood examination	97
1.7	Newer 'molecular' diagnostic methods	98
1.8	Distinguishing tuberculosis from other conditions	98
	<i>Some stories about diagnosis</i>	99
1.9	Complications	103
2:	Tuberculous Pleural Effusion and Empyema	104
2.1	How the pleura is affected	104
2.2	How it shows clinically	104
2.3	How to investigate it	105
2.4	Other conditions which have to be distinguished	106
2.5	Management	106
2.6	End result	106
3:	Miliary Tuberculosis in Adults	107
3.1	How it arises	107
3.2	Why diagnosing it is particularly important	107
3.3	How it shows clinically in adults	107
3.4	How to diagnose miliary tuberculosis	109
3.5	How to treat it	110
	<i>Two stories about miliary tuberculosis</i>	111

Chapter 4	Non-pulmonary Tuberculosis in Adults	115
1:	Tuberculosis of Upper Respiratory Tract: Epiglottis, Larynx, Pharynx	115
1.1	How it shows clinically	115
1.2	Distinguishing it from other diseases	115
1.3	Management	116
2:	Tuberculosis of Mouth, Tonsils and Tongue	116
3:	Tuberculous Meningitis	116
3.1	How it arises	116
3.2	How it shows in the patient	117
3.3	Diagnosis	117
4:	Tuberculosis of the Pericardium	118
4.1	How it arises	118
4.2	How it shows in the patient (clinical features)	118
4.3	Diagnosis	120
4.4	Treatment	120
	<i>A case of tuberculous pericarditis in a boy aged 9½ years</i>	121
5:	Lymph Node Tuberculosis	122
5.1	General comments	122
5.2	Treatment	122
6:	Tuberculosis of Bones and Joints (see page 62)	123
7:	Renal and Urinary Tract Tuberculosis	123
7.1	How it arises	123
7.2	How it may show in the patient (clinical features)	123
7.3	How to diagnose it	124
	<i>A case of genito-urinary tuberculosis</i>	125
8:	Tuberculosis of Female Genital Tract	126
8.1	How it arises	126
8.2	How it shows in the patient	126
8.3	Investigations	126
8.4	Treatment	127
9:	Tuberculosis of Male Genital Tract	127
9.1	How it arises	127
9.2	How it shows in the patient (clinical features)	127
9.3	Investigations	127
9.4	Diagnosis	127
9.5	Treatment	128
10:	Intestinal/Peritoneal Tuberculosis	128
10.1	How it arises	128
10.2	How it shows in the patient (clinical features)	128
10.3	Diagnosis	129
10.4	Treatment	129
10.5	Fistula-in-ano	129
11:	Tuberculosis of the Eye (see page 69)	130
12:	Adrenal Tuberculosis	130
12.1	General comments	130
12.2	Treatment	130
13:	Cutaneous (skin) and Subcutaneous (abscesses) Tuberculosis	131
13.1	Primary lesions (see page 72)	131
13.2	Erythema nodosum	131
13.3	Miliary lesions	132
13.4	Verrucous tuberculosis	132
13.5	Ulcers of mouth, nose and anus	132
13.6	Scrofuloderma	132
13.7	Lupus vulgaris	132
13.8	Tuberculides	132
13.9	Treatment	133

Chapter 5 Tuberculosis, HIV (Human Immunodeficiency Virus) Infection and Aids (Acquired ImmunoDeficiency Syndrome)	135
1: Background	135
1.1 HIV and AIDS	135
1.2 The HIV virus	136
1.3 Geographical spread	136
1.4 Drugs	137
1.5 Diagnosis and testing	137
2: Effect of HIV on Control Programmes	137
2.1 Disease prevalence	137
2.2 Sputum testing	138
2.3 Drug reactions	138
2.4 Separation of patients	138
2.5 HIV-positive staff	138
2.6 Needles	138
3: How Tuberculosis with HIV Shows Clinically	138
4: Note on WHO Case Definitions for AIDS	139
4.1 Where HIV testing is not available	139
4.2 Where HIV testing is available	140
4.3 Children	140
5: Non-Tuberculous Complications of HIV Infection	141
5.1 Early HIV illness	141
5.2 Kaposi's sarcoma	141
5.3 <i>Pneumocystis carinii</i> pneumonia (PCP)	142
5.4 Pulmonary cryptococcosis	142
5.5 Nocardiasis	142
6: HIV Testing and Counselling	142
6.1 HIV testing	142
6.2 Laboratory testing	143
6.3 Pre-test counselling	143
6.4 Post-test counselling	143
7: Treatment of Tuberculosis	144
7.1 Short-course treatment	144
7.2 Mortality	144
7.3 Prognosis	144
7.4 Side-effects	144
7.5 Streptomycin	144
8: Treatment of HIV Infection	145
9: Treatment of Other Complications of HIV Infection	145
9.1 Sexually transmitted diseases	145
9.2 Skin and mouth problems	147
9.3 Gastrointestinal problems	148
9.4 Respiratory problems	148
9.5 Neurological problems	149
9.6 Septicaemia	149
9.7 Anaemia	149
9.8 Thrombocytopenia	150
10: Preventive Treatment with Isoniazid	150
11: BCG Vaccination (see page 86)	150
12: Conclusions	150
References	150
Appendix on Protection of Health Staff from Infection by HIV	151
Chapter 6 Treatment of Tuberculosis	153
1: General Guide to Treatment	153
1.1 Introduction	153
1.2 When to treat (criteria for treatment)	153

1.3	Non-pulmonary tuberculosis	156
1.4	Supervision of treatment	156
1.5	Management of patients who fail to attend (defaulters)	158
1.6	Preventing the patient stopping treatment too early (preventing default)	159
1.7	Where to arrange the treatment centre which the patient will attend for continuation phase of treatment	160
1.8	Choosing staff	161
1.9	Patients' personal problems	161
1.10	Drug resistance	161
1.11	Follow-up	162
1.12	Sputum testing	162
1.13	Outpatient or hospital treatment	162
1.14	Isolation	163
1.15	Contact examination (see page 23)	164
1.16	Work	164
1.17	Lifestyle	164
1.18	Pregnancy	164
1.19	The newborn child	165
2:	Chemotherapy for Newly Diagnosed Patients	165
2.1	National Tuberculosis Programmes	165
2.2	When there is no National Tuberculosis Programme	166
2.3	Brief method for summarising regimens	166
2.4	Alternative treatment regimens	166
2.5	Drug doses	168
2.6	Fixed-dose drug combinations (FDCs)	170
2.7	8-month regimen avoiding rifampicin in the continuation phase	170
2.8	12-month regimen avoiding rifampicin and pyrazinamide	170
2.9	Treatment in special situations	171
2.10	Watch out for adverse effects of drugs. A symptom-based approach	172
	<i>Stories about treatment</i>	172
3:	Treatment of Non-pulmonary Tuberculosis: Medical Treatment	174
3.1	Pleural effusion	174
3.2	Pericardial effusion	174
3.3	Spinal tuberculosis	174
3.4	Genito-urinary disease	175
3.5	Tuberculous meningitis	175

Reference section

177

Appendix A: Details of Drug Use

179

1:	Drugs Used in Chemotherapy	179
1.1	General	179
1.2	Isoniazid	179
1.3	Rifampicin	180
1.4	Streptomycin	181
1.5	Ethambutol	183
1.6	Pyrazinamide	183
1.7	Thioacetazone	184
1.8	Summary of toxic reactions to the main anti-tuberculosis drugs	184
1.9	'Second-line' drugs	185
2:	Management of Reactions to Anti-tuberculosis Drugs	186
2.1	Hypersensitivity (allergic) reactions	186
2.2	Hepatitis	188
3:	Corticosteroids in the Management of Tuberculosis	188
3.1	Possible indications for corticosteroid drugs in tuberculosis	188
3.2	Precautions	189
3.3	Dosage	189

4: Management of Patients whose Chemotherapy has Apparently Failed	189
4.1 Suspecting treatment failure	189
4.2 Investigations	190
4.3 Too short treatment	190
4.4 Probable drug resistance	191
4.5 Managing the patient with relapse	191
4.6 Probable multiple drug resistance	192
Appendix B: Surgery in Tuberculosis	194
1: Pleuro-pulmonary Disease	194
2: Lymph Node Disease	194
3: Bone and Joint Disease	195
4: Genito-urinary Disease	195
5: Abdominal Tuberculosis	195
6: Tuberculosis of the Thyroid and Breast	195
7: Tuberculosis of the Pericardium	196
Appendix C: Preventive Therapy and Chemoprophylaxis	197
1: Drugs	197
2: Use	197
3: Doubtfully Active Tuberculosis	198
Appendix D: Infections with Opportunistic Mycobacteria	199
Appendix E: Tuberculin Testing	200
1: Tuberculins	200
1.1 Recommended tuberculin	200
1.2 Storage	200
2: Tuberculin tests	201
2.1 Mantoux test	201
2.2 Reading and interpreting the result	201
3: Heaf Test	203
3.1 Method	203
3.2 Reading the test	203
4: Interpreting a Tuberculin Test	204
4.1 Epidemiology	205
4.2 Diagnosis	205
Reference	205
Appendix F: Gastric Suction in Children	206
Glossary	207
References	215
Index	218

1

General Background to Clinical Tuberculosis

1: INTRODUCTION

1.1 About this book

This book is written for non-specialist hospital doctors, doctors in primary health care and other health professionals who may meet tuberculosis in the course of their work. **Almost all patients with newly diagnosed tuberculosis can be cured if properly treated.** Many will die if they are not properly treated. Therefore, as a responsible doctor or health worker

- DO NOT miss the diagnosis
- DO then give the correct treatment for the full period of time.

More than that, **GOOD TREATMENT IS THE MOST IMPORTANT FORM OF PREVENTION.** It makes infectious patients non-infectious. This reduces the passing on of infection in the community.

Tuberculosis is a challenging disease. Sometimes trying to make the diagnosis is like trying to solve a detective story. But if you succeed in solving the problem, you can be sure of a happy ending to the story. Modern treatment is highly successful in curing tuberculosis even in patients already infected with the HIV (AIDS) virus.

1.2 Some of the things you should know

If you are going to play your part in helping your patients, and in controlling tuberculosis in your country, you must know something about its cause. You must know where infection comes from. You must know how most people control that infection and do not get ill, but why some develop disease. The general public will also expect you to know something about the best way of **preventing tuberculosis.** If your country has a **national programme** for tuberculosis control, **YOU SHOULD KNOW ABOUT IT** and should play your part in making it work.

1.3 The world problem of tuberculosis

In many industrialised countries money, resources, high standards of living, and widespread chemotherapy in the last 40 years, have helped to reduce tuberculosis to a relatively minor problem. But in poorer countries it remains almost as big a problem as ever. Indeed, as their populations have increased and their tuberculosis rates have only slightly decreased, **there are probably more tuberculosis patients in the world today than there were 20 years ago.** WHO has estimated that the total number of cases in the world will rise from 7.5 million in 1990 to 10.2 million in the year 2000. Total deaths will rise from 2.5 to 3.5 million. The rise will be due partly to increases in population in developing countries and partly to the spread of the HIV virus (p 135). These rises could be stopped if many countries set up effective Tuberculosis Control Programmes (p 15).

1.4 The outlook

This may all sound depressing, but in many poor countries with high tuberculosis rates modern programmes of mass treatment efficiently applied, are showing excellent results. There are even signs that this success is beginning to make tuberculosis a little less common in some of these countries where HIV infection is low. In industrialised countries the rate of new cases (incidence rate) fell by 6–12 per cent a year after the widespread use of chemotherapy. After the introduction of good National Control Programmes WHO reports declines per year of 5 per cent for Chile, 7 per cent for Cuba, 8 per cent for Uruguay and 7 per cent for the Republic of Korea. These figures show what can be achieved. But with the explosion of HIV infection in Africa, and now in Asia, it will need very major national and international effort to achieve such results throughout the world. An increasing number of countries have made a good start. We hope you will make your own contribution in your own country.

1.5 Tuberculin surveys and annual numbers of new cases

It has been calculated that **for every 1 per cent of new annual infections (new tuberculin positives among the population) there will be 50–60 new smear positive cases of pulmonary tuberculosis per 100,000 population per year and an equal number of either smear-negative or non-pulmonary cases.** Using this calculation a sample tuberculin survey can be used to calculate the probable number of new cases per year in a country. (Not all experts accept the value of this method.)